# Primaquine

```text
DRUG INFORMATION

  ADULT
    - Primaquine phosphate Tablets should be administered concurrently to eradicate the
      exoerythrocytic parasites in adults at a dosage of 1 tablet (equivalent to 15 mg
      base) daily for 14 days.
      Source: US FDA label for primaquine (Primaquine Phosphate), section 'dosage and
      administration', retrieved 2026-08-29
    - Primaquine phosphate Tablets are recommended only for the radical cure of vivax
      malaria, the prevention of relapse in vivax malaria, or following the termination
      of chloroquine phosphate suppressive therapy in an area where vivax malaria is
      endemic.
      Source: US FDA label for primaquine (Primaquine Phosphate), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Safety and effectiveness in pediatric patients have not been established.
      Primaquine phosphate Tablets are contraindicated in breastfeeding women when the
      infant is found to be G6PD deficient or the G6PD status of the infant is unknown
      (see CONTRAINDICATIONS and WARNINGS, Nursing Mothers ).
      Source: US FDA label for primaquine (Primaquine Phosphate), section 'pediatric
      use', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for primaquine (Primaquine
      Phosphate), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for primaquine (Primaquine
      Phosphate), retrieved 2026-08-29

  PREGNANCY   [ AVOID ]
    The label says not to use it. Read the quote below before deciding.
    - Safe usage of Primaquine phosphate Tablets in pregnancy has not been established.
      Source: US FDA label for primaquine (Primaquine Phosphate), section 'pregnancy',
      retrieved 2026-08-29
    - Primaquine is contraindicated in pregnant women.
      Source: US FDA label for primaquine (Primaquine Phosphate), section 'pregnancy',
      retrieved 2026-08-29
    - The use of Primaquine phosphate Tablets during pregnancy may cause hemolytic
      anemia in a G6PD-deficient fetus.
      Source: US FDA label for primaquine (Primaquine Phosphate), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING   [ AVOID ]
    The label says not to use it. Read the quote below before deciding.
    - A breastfed infant with G6PD deficiency is at risk for hemolytic anemia from
      exposure to primaquine.
      Source: US FDA label for primaquine (Primaquine Phosphate), section 'nursing
      mothers', retrieved 2026-08-29
    - Infant G6PD status should be checked before breastfeeding begins.
      Source: US FDA label for primaquine (Primaquine Phosphate), section 'nursing
      mothers', retrieved 2026-08-29
    - Primaquine phosphate Tablets are contraindicated in breastfeeding women when the
      infant is found to be G6PD deficient or the G6PD status of the infant is unknown
      (see CONTRAINDICATIONS ).
      Source: US FDA label for primaquine (Primaquine Phosphate), section 'nursing
      mothers', retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)